Details

Autor(en) / Beteiligte

• Dong, Hui
• Zhou, Lang
• Yang, Luyu
• Lu, Huizhi
• Cao, Song
• Song, Huimin
• Fu, Shouzhi

Titel

β-Blockers could improve the 28-day and 3-year survival of patients with end-stage renal disease: a retrospective cohort study

Ist Teil von

• International urology and nephrology, 2023-06, Vol.55 (6), p.1597-1607

Ort / Verlag

Dordrecht: Springer Netherlands

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Background Dialysis or non-dialysis end-stage renal disease (ESRD) patients are accompanied by cardiovascular disease (CVD) or hypertension. We aimed to study the effect of a common treatment for CVD, β-blockers, on the survival of ESRD patients, improving their prognosis from the perspective of drug therapy. Methods It was a retrospective cohort study using the Medical Information Mart for Intensive Care dataset. ESRD patients in the intensive care unit from June 2001 to October 2012 were included. We examined the effect of using versus not using β-blockers in the overall population and subgroups with the risk of 28-day and 3-year mortality through Cox proportional hazards models and Kaplan–Meier curves. Results A total of 1639 participants were included with 371 (22.64%) β-blockers users. There were 315 (19.22%) 28-day and 970 (59.18%) 3-year mortality events during follow-up. Using β-blockers in overall ESRD patients could reduce all-cause 28-day mortality [adjusted hazard ratio (HR) 0.450, 95% confidence interval (CI) 0.325–0.624] and 3-year mortality (adjusted HR 0.695, 95% CI 0.589–0.821). This result was consistent among subgroups (ESRD without hypertension: adjusted HR 0.412, 95% CI 0.289–0.588; with CVD: adjusted HR 0.478, 95% CI 0.321–0.711; without CVD: adjusted HR 0.448, 95% CI 0.248–0.810; with dialysis: adjusted HR 0.471, 95% CI 0.320–0.694) in 28-day mortality, and the 3-year mortality was consistent. In ESRD patients with hypertension and without dialysis subgroups, β-blockers had no effect on survival. Conclusion Using β-blockers could reduce the risk of 28-day and 3-year mortality in ESRD patients, including those with CVD. This study provided a reference for the treatment of β-blockers in patients with ESRD.